Richard Peter Marshall - 17 Jun 2026 Form 4 Insider Report for Serina Therapeutics, Inc. (SER)

Reporting relationship: Director
Issuer ticker: SER
Reported as of: 17 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jun 2026, 19:12:52 UTC
Prior SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Steven Ledger, Attorney in Fact

Key filing fact

Richard Peter Marshall filed Form 4 for Serina Therapeutics, Inc. (SER) on 22 Jun 2026.

Key facts

This page summarizes Richard Peter Marshall's Form 4 filing for Serina Therapeutics, Inc. (SER).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Jun 2026, 19:12.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002016188 Primary reporting owner

Marshall Richard Peter

Relationship: Director
Address: 601 GENOME WAY, SUITE 2001, HUNTSVILLE
Signature: /s/ Steven Ledger, Attorney in Fact
Signature date: 22 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SER transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +15,250
Change %
Price: $0.000000^*
Shares after: 15,250
Date: 17 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,250
Exercise price: $1.98
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.